Trials / Completed
CompletedNCT00414999
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
A Phase 1, Double-Masked, Placebo-Controlled, Dose-Escalation Study (in Two Parts) of TG100801 and a Colored Vehicle in Adult Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- TargeGen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies, and may have great utility in the treatment of diseases such as AMD. The purpose of this study is to assess the safety, ocular tolerability, and blood pharmacokinetics of TG100801 at escalating doses in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG100801 |
Timeline
- Start date
- 2006-11-01
- Completion
- 2007-02-01
- First posted
- 2006-12-22
- Last updated
- 2007-07-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00414999. Inclusion in this directory is not an endorsement.